Scoop: With investor interest dried up in microbiome therapies, DermBiont pivots to other topicals and nears close of Series B

Kyle LaHucik

Senior Reporter

DermBiont axed trials of its original lead dermatology gel, the biotech confirmed to Endpoints News, and with little investor appetite for microbiome-based therapies, the company …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Scoop: With investor interest dried up in microbiome therapies, DermBiont pivots to other topicals and nears close of Series B

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

Viking CEO on ‘shocking’ market reaction to oral obesity data, preparing for Phase 3

Sana narrows focus again to zero in on diabetes and autoimmune disease

Vertex makes money from sickle cell therapy Casgevy

The election is Tuesday. What’s at stake for the pharma industry?

Is there room for MASH drugs in a GLP-1 world?

Gene therapies don’t have to cost $4 million: New production platforms reduce development costs and risks

Scoop: With in­vestor in­ter­est dried up in mi­cro­bio­me ther­a­pies, DermBiont piv­ots to oth­er top­i­cals and nears close of Se­ries B

Senior Reporter

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

Scoop: With investor interest dried up in microbiome therapies, DermBiont pivots to other topicals and nears close of Series B